Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Palmitic acid
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

Henan Tianfu Chemical Co., Ltd.
China
Product Name: Acarbose 56180-94-0
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson
Email: info@tianfuchem.com

56180-94-0

56180-94-0 structure

56180-94-0 structure

Name: Acarbose
Chemical Name: acarbose
CAS Number: 56180-94-0
Molecular Formula: C₂₅H₄₃NO₁₈
Molecular Weight: 645.605
Catalog: API Hormone and endocrine-regulating drugs Pancreatic hormones and other blood sugar regulating drugs
Create Date: 2018-02-05 08:00:00
Modify Date: 2026-06-30 12:34:06
Acarbose is an inhibitor of alpha glucosidase, an anti-diabetic drug.

Name	acarbose
Synonyms	Acbose API roxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-d-glucopyranosyl-o Acbos 4,6-Dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino}-α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-β-D-glucopyranose MFCD00869592 O-4,6-Dideoxy-4-[[[1S-(1α,4α,5β,6α)]-4,5,6-trihydroxy-3-(hydroxyMethyl)-2-cyclohexen-1-yl]amino]-α-D-glucopyranosyl-O-α-D-glucopyranosyl-D-glucose acarviostatin I01 Acbose extrapure Acboser Acbose Hydrate 4",6"-dideoxy-4"-[(1 S )-(1,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2-cyclohexenylamino]maltotriose O-4,6-DIDEOXY-4-[[[1S-(1A,4A,5BETA,6A)]-4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)-2-CYCLOHEXEN-1-YL]AMINO]-ALPHA-D-GLUCOPYRANOSYL-O-ALPHA-D-GLUCOPYRANOSYL-D-GLUCOSE 4)-O-a-D-glucopyranosyl-(1® (2R,3R,4R,5S,6R)-5-((2R,3R,4R,5S,6R)-5 high qualtiy Acbose 5 O-4,6-Dideoxy-4-[[[1S-(1a,4a,5b,6a)]-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-a-D-glucopyranosyl-O-a-D-glucopyranosyl-D-gluco- se Acbose //BP EINECS 260-030-7 Acbose Hydrate> O-4,6-Dideoxy-4-[[[1S-(1a,4a,5b,6a)]-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-a-D-glucopyranosyl-(1®4)-O-a-D-glucopyranosyl-(1®4)-D-glucose Bay g 5421：Glucobay Ascarbose ACBOSE DC ANULES Bay g 5421 Acbose AMylostatin J, Bay g 5421, alpha-GHI Acbose for identification CRS Acbose (1.0mg/ml in DMSO) (2R,3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-méthyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxyméthyl)cyclohex-2-én-1-yl]amino}tétrahydro-2H-pyran-2-yl]oxy}-3,4-dihydro Acbose 5 O-4,6-Dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-α-D-glucopyranosyl-O-α-D-glucopyranosyl-D-Glucose d-glucose,o-4,6-dideoxy-4-(((1s-(1-alpha,4-alpha,5-beta,6-alpha))-4,5,6-trihyd Acbose CRS Acbose, alpha-glucosidase inhibitor (3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S, 5S,6R)-3,4-dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4 ,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1- yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxy methyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2, 3 4-trio Acbose for peak identification CRS (2R,3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-Dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}tetrahydro-2H-pyran-2-yl]oxy}-3,4-dihydro BAY-g 5421 O-4，6-Dideoxy-4-[[[1S(1α，4α，5β，6α-)-4，5，6-trihydrDxy-3-(hydroxymethyl)-2-cyclohexen-1-y1]amino]- α-D-glucopyranosyl-(1→4)-O-α-D-ducopyranosyl-(1→4)-D-glucose O-4,6-DIDEOXY-4-[[[1S-(1A,4A,5BETA,6A)]-4,5,6-TRIHYDROXY-3-(HYDROXYMETHY Acbose 56-0 D-Glucose, O-4,6-dideoxy-4-[[4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-α-D-glucopyranosyl-(1→4)-O-α-D-glucopyranosyl-(1→4)-, [1S-(1α,4α,5β,6α)] AcboseQ: What is Acbose Q: What is the CAS Number of Acbose Q: What e the applications of Acbose (2R,3R,4R,5R)-4-(((2R,3R,4R,5S,6R)-5-(((2R,3R,4S,5S,6R)-3,4-Dihydroxy-6-methyl-5-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl)amino)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2,3,5,6-tetrahydroxyhexanal D-Glucose,O-4,6-dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxyMethyl)-2-cyclohexen-1-yl]amino]-a-D-glucopyranosyl-(1® Acbose (COLD SHIPMENT REQUIRED) (3S,5S)-5-[(2R,3S,5S)-5-[(2R,3S,5S)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol 4,6-Dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-β-D-glucopyranose O-4,6-Dideoxy-4-[[[1S-(1a,4a,5,6a)]-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-a-D-glucopyranosyl-O-a-D-glucopyranosyl-D-glucose D-Glucose, O-4,6-dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-α-D-glucopyranosyl-(1→4)-O-α-D-glucopyranosyl-(1→4) Acbose Tablets Precos 4-O-[4-O-[4-[[(1S,4R,5S,6S)-4,5,6-Trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-4,6-dideoxy-α-D-glucopyranosyl]-α-D-glucopyranosyl]-D-glucopyranose A.3-aminopropane-1-sulfonicacid(homotaurine) (3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S, 5S,6R)-3,4-dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4 ,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1- yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxy methyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2, 3 4-triol Ascbose 5-[5-[3,4-DIHYDROXY-6-METHYL-5-[[4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)-1-CYCLOHEX-2-ENYL]AMINO]OXAN-2-YL]OXY-3,4-DIHYDROXY-6-(HYDROXYMETHYL)OXAN-2-YL]OXY-6-(HYDROXYMETHYL)OXANE-2,3,4-TRIOL (2R,3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-méthyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxyméthyl)cyclohex-2-én-1-yl]amino}tétrahydro-2H-pyran-2-yl]oxy}-3,4-dihydroxy-6-(hydroxyméthyl)tétrahydro-2H-pyran-2-yl]oxy}-6-(hydroxyméthyl)tétrahydro-2H-pyran-2,3,4-triol Acbose fom Actinoplanes sp. ca. 100 FIP-AIU/mg (2R,3R,4R,5R)-4-(((2R,3R,4R,5S,6R)-5-(((2R,3R,4S,5S,6R)-3,4-Dihydroxy-6-methyl-5-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl)amino)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2,3,5,6 4-[[5-[[3,4-dihydroxy-6-methyl-5-[[2,3,4-trihydroxy-5-(hydroxymethyl)cyclohexyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-2,3,5,6-tetrahydroxyhexanal Acbose (Acbosum) (2R,3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-Dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}tetrahydro-2H-pyran-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol Acbose (Acbosum) (Mixture ofDiastereomers) bay-g5421 alpha-d-glucopyranosyl 4",6"-Dideoxy-4"-([1S]-[1,4,6/5]-4,5,6-trihydroxy-3-hydroxymethyl-2-yclohexenylamino)-maltotriose Prandase Precose Glucobay

Description	Acarbose is an inhibitor of alpha glucosidase, an anti-diabetic drug.
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
In Vitro	Acarbose (1, 2, and 3 μM) dose- and time-dependently inhibits TNF-α-induced VSMC proliferation and migration. Acarbose (1, 2, and 3 μM) dose-dependently decreases β-galactosidase, Ras expression and increased p-AMPK expression in TNF-α pre-treated A7r5 cells[2].
In Vivo	Acarbose (300 mg/60 kg body weight) decreases the fasting blood glucose, and regulates the glucose tolerance of DM rats without body weight loss. Acarbose significantly suppresses serum IL6 and TNF-α in DM rats[1]. Acarbose (2.5 and 5.0 mg/kg) significantly and dose-dependently decreases the intensity of neointimal IL-6, TNF-α, and iNOS staining, and significantly increases the intensity of neointimal p-AMPK staining. Acarbose (2.5 and 5.0 mg/kg) significantly and dose-dependently decreases neointimal Ras and β-galactosidase expression in HCD-fed rabbits without body weight loss[2].
Cell Assay	Cell viability is determined using the MTT assay. Cells are seeded in 24-well culture plates at a density of 2×104 cells/well, incubated for 48 h, treated with acarbose at varying concentrations (0.5, 1.0, 2.0, 3.0, and 5.0 μM) for 24 h; or pre-treated with TNF-α (20 ng/mL) for either 24 h or 48 h to evaluate the dose-dependent effects of acarbose on VSMC growth and viability, cultured with 0.5 mg/mL MTT at 37°C in a humidified atmosphere of 5% CO2 for another 4 h, and solubilized with isopropanol. The viable cell number varies directly with the concentration of formazan product measured spectrophotometrically at 563 nm.
Animal Admin	Twenty-four male New Zealand white rabbits, weighing 2500 g are used. They are individually housed in metal cages in an air-conditioned room (22 ± 2°C, 55 ± 5% humidity), under a 12 h light/12 h dark cycle with free access to food and water. All rabbits are randomLy assigned to four groups of 6 animals each and are fed either standard chow (Group I), high cholesterol diet (HCD; containing 95.7% standard Purina chow + 3% lard oil + 0.5% cholesterol) (Group II), HCD diet and 2.5 mg/kg per day acarbose (Group III), or HCD diet and 5.0 mg/kg per day acarbose (Group IV). At the end of the 25 weeks, all rabbits are sacrificed by exsanguination under deep anesthesia with pentobarbital (30 mg/kg i.v.) injected via the marginal ear vein. Serum is stored at −80°C prior to measurement of serum values. The aortic arch and thoracic aortas are carefully removed to protect the endothelial lining, and are collected and freed of adhering soft tissue.
References	[1]. Zhang Q, et al. Acarbose Reduces Blood Glucose by Activating miR-10a-5p and miR-664 in Diabetic Rats. PLoS One. 2013 Nov 18;8(11):e79697. [2]. Chan KC, et al. Pleiotropic effects of acarbose on atherosclerosis development in rabbits are mediated via upregulating AMPK signals. Sci Rep. 2016 Dec 7;6:3864

Density	1.7±0.1 g/cm3
Boiling Point	971.6±65.0 °C at 760 mmHg
Melting Point	165-170ºC
Molecular Formula	C₂₅H₄₃NO₁₈
Molecular Weight	645.605
Flash Point	541.4±34.3 °C
Exact Mass	645.247986
PSA	321.17000
LogP	-4.16
Vapour Pressure	0.0±0.6 mmHg at 25°C
Index of Refraction	1.689

CHEMICAL IDENTIFICATION

RTECS NUMBER :: LZ7153000

CHEMICAL NAME :: D-Glucose, O-4,6-dideoxy-4-(((1S-(1-alpha,4-alpha,5-beta,6-alpha ))-4,5,6-trihydroxy-3- (hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-gluc opyranosyl-(1-4)-O-al pha- D-glucopyranosyl-(1-4)-

CAS REGISTRY NUMBER :: 56180-94-0

LAST UPDATED :: 199704

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C25-H43-N-O18

MOLECULAR WEIGHT :: 645.69

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 360 mg/kg/60D-I

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - other changes Liver - liver function tests impaired

REFERENCE :: AIMEAS Annals of Internal Medicine. (American College of Physicians, 4200 Pine St., Philadelphia, PA 19104) V.1- 1927- Volume(issue)/page/year: 124,931,1996

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 24 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,2,1995

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 12 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,2,1995

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 6 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,2,1995

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 24 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,2,1995

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 12 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,2,1995 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 72800 mg/kg/13W-I

TOXIC EFFECTS :: Gastrointestinal - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other Enzymes

REFERENCE :: KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 23,4341,1989

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Safety Phrases	24/25
RIDADR	NONH for all modes of transport
RTECS	LZ7153000
HS Code	29400090

68107-35-7 structure

68107-35-7

~60%

56180-94-0 structure

56180-94-0

Literature: Shibata, Yasushi; Ogawa, Seiichiro Carbohydrate Research, 1989 , vol. 189, p. 309 - 322

117011-93-5 structure

117011-93-5

~%

56180-94-0 structure

56180-94-0

Literature: Journal of the Chemical Society, Chemical Communications, , p. 605 - 606

Precursor 1
68107-35-7
DownStream 0

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.